{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T23:12:47Z","timestamp":1714777967249},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/jcp.0b013e3180ca83b1","type":"journal-article","created":{"date-parts":[[2007,7,9]],"date-time":"2007-07-09T08:05:22Z","timestamp":1183968322000},"page":"329-337","source":"Crossref","is-referenced-by-count":9,"title":["Olanzapine Versus Chlorpromazine in the Treatment of Schizophrenia"],"prefix":"10.1097","volume":"27","author":[{"given":"Martin","family":"Dossenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Treuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila","family":"Kryzhanovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mete","family":"Saylan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00019053-199201030-00007","article-title":"Utilisation of psychotropic drugs in patients of the long stay ward.","volume":"1","author":"El Hefny","year":"1992","journal-title":"Pharmacoeconomics"},{"key":"R2-2-20210128","first-page":"437","article-title":"Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics.","volume":"103","author":"Lin","year":"2004","journal-title":"J Formos Med Assoc"},{"key":"R3-2-20210128","first-page":"CD000284","article-title":"Chlropromazine versus placebo for schizophrenia.","volume":"2","author":"Thornley","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1176\/ajp.155.7.914","article-title":"Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.","volume":"155","author":"Conley","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R5-2-20210128","first-page":"341","article-title":"The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry. 1999;60:41-44.","volume":"60","author":"Howanitz","year":"1999","journal-title":"Erratum in: J Clin Psychiatry"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1997.tb10162.x","article-title":"A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia.","volume":"96","author":"Peuskens","year":"1997","journal-title":"Acta Psychiatr Scand"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/070674370304801107","article-title":"From chlorpromazine to clozapine-antipsychotic adverse effects and the clinician's dilemma.","volume":"48","author":"Abidi","year":"2003","journal-title":"Can J Psychiatry"},{"key":"R8-2-20210128","first-page":"99","article-title":"Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.","volume":"37","author":"Dunlop","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00002018-200225150-00005","article-title":"Glucose intolerance with atypical antipsychotics.","volume":"25","author":"Hedenmalm","year":"2002","journal-title":"Drug Saf"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.jcp.0000150224.38630.ae","article-title":"Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.","volume":"25","author":"Lambert","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2004.12.003","article-title":"Metabolic risk during antipsychotic treatment.","volume":"26","author":"Newcomer","year":"2004","journal-title":"Clin Ther"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004850-199705000-00001","article-title":"A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia.","volume":"12","author":"Hong","year":"1997","journal-title":"Int Clin Psychopharmacol"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.","volume":"76","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/009286159302700442","article-title":"Ordinal data with few categories: how should they be analyzed?","volume":"27","author":"Rahlfs","year":"1993","journal-title":"Drug Information Journal"},{"issue":"suppl 3","key":"R21-2-20210128","first-page":"S369","article-title":"Olanzapine vs. chlorpromazine-6 weeks treatment of acute schizophrenia.","volume":"11","author":"Kostakoglu","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"issue":"suppl 3","key":"R22-2-20210128","first-page":"S369","article-title":"Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine.","volume":"11","author":"Kostakoglu","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"issue":"suppl 5","key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0924-977X(99)80354-X","article-title":"Olanzapine compared to chlorpromazine in acute schizophrenia.","volume":"9","author":"Loza","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1527-3458.2000.tb00155.x","article-title":"Olanzapine: Preclinical and clinical profiles of a novel antipsychotic agent.","volume":"6","author":"Tollefson","year":"2000","journal-title":"CNS Drug Rev"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4088\/JCP.v62n1003","article-title":"The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.","volume":"62","author":"Davis","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl 10","key":"R27-2-20210128","first-page":"13","article-title":"Safety of olanzapine.","volume":"58","author":"Beasley","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis.","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1517\/14656566.2.10.1571","article-title":"Antipsychotic medication: effects on regulation of glucose and lipids.","volume":"2","author":"Kato","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200708000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T13:43:29Z","timestamp":1708091009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200708000-00002"}},"subtitle":["A Pooled Analysis of Four 6-Week, Randomized, Open-Label Studies in the Middle East and North Africa"],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3180ca83b1","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}